IPBiz: Teva and AstraZeneca's EP patent on Seroquel

Sunday, January 23, 2011

Teva and AstraZeneca's EP patent on Seroquel

Reuters reports: Israel's Teva Pharmaceutical Industries has launched a High Court action in London to revoke the European patent for Seroquel, an anti-depressant [used in cases of schizophrenia and bipolar] developed by AstraZeneca

The US Hatch-Waxman case over Seroquel (quetiapine) began in DNJ in 2005. See IPBiz post Teva makes paragraph IV filing against AstraZeneca over Seroquel

0 Comments:

Post a Comment

<< Home

Name: Lawrence B. Ebert

I'm a patent lawyer located in central New Jersey. I have a J.D. from the University of Chicago and a Ph.D. from Stanford University, where I studied graphite intercalation compounds at the Center for Materials Research. I worked at Exxon Corporate Research in areas ranging from engine deposits through coal and petroleum to fullerenes. An article that I wrote in The Trademark Reporter, 1994, 84, 379-407 on color trademarks was cited by Supreme Court in Qualitex v. Jacobson, 514 US 159 (1995) and the methodology was adopted in the Capri case in N.D. Ill. An article that I wrote on DNA profiling was cited by the Colorado Supreme Court (Shreck case) and a Florida appellate court (Brim case). I was interviewed by NHK-TV about the Jan-Hendrik Schon affair. I am developing ipABC, an entity that combines rigorous IP analytics with study of business models, to optimize utilization of intellectual property. I can be reached at C8AsF5 at yahoo.com.

View my complete profile

IPBiz

Sunday, January 23, 2011

Teva and AstraZeneca's EP patent on Seroquel

0 Comments:

About Me

Previous Posts